Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
High Blood Pressure & Cardiovascular Prevention
Erschienen in: High Blood Pressure & Cardiovascular Prevention 6/2022

01.11.2022 | Review article

Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis

verfasst von: Sadek Mostafa, Hosam Shabana, Farag Khalil, Ismail Mohamed El Mancy, Hendawy Abdel-Moety Zedan, Ahmed Elmoursi, Ibrahim Ghounim Ramadan, Saad El Deen Mohamed, Arafat Kassem, Islam Shawky Kamel

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Hypertension represent the commonest cause of death in 2017. Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension. The perindopril–amlodipine combination showed a significant effect in reduction of the elevated BP and the cardiovascular complications.

Aim

To evaluate the efficacy and safety of a fixed-dose single-pill combination of perindopril–amlodipine in hypertensive patients.

Methods

We searched PubMed, Medline, SCOPUS, and Web of Science for relevant clinical trials. Quality appraisal was evaluated according to GRADE and we assessed the risk of bias using Cochrane’s risk of bias tool. We included the following outcomes: systolic blood pressure, diastolic blood pressure, pulse pressure, mean blood pressure, heart rate, cough, dizziness, headache, and peripheral edema. We performed the analysis of homogeneous data under the fixed-effects model, while analysis of heterogeneous data was analyzed under the random-effects model. We conducted a meta-regression according to the dose.

Results

We included ten clinical trials. The pooled analysis showed that there was a significant reduction of the systolic blood pressure, diastolic blood pressure, pulse plessure, mean blood pressure, and heart rate after the the perindopril–amlodipine combination (MD = 18.96 [14.32, 23.60], P < 0.0001), (MD = 11.90 [8.45, 15.35], P < 0.0001), (MD = 8.44 [6.91, 9.97], P = 0.0001), (MD = 13.07 [5.86, 20.29], P = 0.0004), and (MD = 2.93 [0.89, 4.96], P = 0.005), respectively. The results of the meta-regression revealed that the efficacy is increased by increasing the dose (P < 0.001)

Conclusion

The use of the perindopril–amlodipine combination had a significant effect on the reduction of SBP, DBP, mean blood pressure, pulse pressure, and HR.
Literatur
1.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical Pr. J Am Coll Cardiol. 2018;71:e127–248.CrossRefPubMed
2.
Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Di. Lancet. 2019.
3.
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol. 2019;77:71–159.CrossRefPubMed
4.
5.
Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M, et al. Heritability of conventional an ambulatory blood pressures: a study in twins. Hypertension. 1995;26:919–24.CrossRefPubMed
6.
7.
Hosseinnezhad A, Black RM, Aeddula NR, Adhikari D, Trivedi N. Glucagon-induced pheochromocytoma crisis. Endocr Pract. 2011;17:e51–4.CrossRefPubMed
8.
Biswas S, Dastidar DG, Roy KS, Pal SK, Biswas TK, Ganguly SB. Complications of hypertension as encountered by primary care physician. J Indian Med Assoc. 2003;101:257–9.PubMed
9.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311:507.CrossRefPubMed
10.
Leape L, Berwick D, Clancy C, Conway J, Gluck P, Guest J, et al. Transforming healthcare: a safety imperative. Qual Saf Heal Care. 2009;18:424–8.CrossRef
11.
Turnbull F. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med. 2005;165:1410.CrossRefPubMed
12.
Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S, et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–35.CrossRefPubMed
13.
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.CrossRefPubMed
14.
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. Br Med J. 2003;326:1427.CrossRef
15.
Dimmitt SB, Stampfer HG. Low drug doses may improve outcomes in chronic disease. Med J Aust. 2009;191:511–3.CrossRefPubMed
16.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B). Lancet. 2005;366:895–906.CrossRefPubMed
17.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9.CrossRefPubMed
18.
19.
20.
21.
Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol. 1994;73:A28–33.CrossRef
22.
Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol. 1997;79:431–5.CrossRefPubMed
23.
24.
Katz A. Microsoft Excel 2010. Style (DeKalb, IL). 2010.
25.
26.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al. Cochrane handbook for systematic reviews of interventions. 2019.
27.
28.
Mancia G, Asmar R, Amodeo C, Mourad J-J, Taddei S, Gamba MAA, et al. Comparison of single-pill strategies first line in hypertension. J Hypertens. 2015;33:401–11.CrossRefPubMed
29.
Laurent S, Parati G, Chazova I, Sirenko Y, Erglis A, Laucevicius A, et al. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. J Hypertens. 2015;33:653–62.CrossRefPubMed
30.
Hu D, Sun Y, Liao Y, Huang J, Zhao R, Yang K. Efficacy and safety of fixed-dose perindopril arginine/amlodipine in hypertensive patients not adequately controlled with amlodipine 5 mg or perindopril tert-butylamine 4 mg monotherapy. Cardiology. 2016;134:1–10.CrossRefPubMed
31.
32.
Visco V, Finelli R, Pascale AV, Giannotti R, Fabbricatore D, Ragosa N, et al. Larger blood pressure reduction by fixed-dose compared to free dose combination therapy of ACE inhibitor and calcium antagonist in hypertensive patients. Transl Med. 2017;16:17–23.
33.
Sobngwi E, Mfeukeu-Kuate L, Kouam M, Tankeu AT, Nganou-Gnindjio CN, Hamadou B, et al. Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: a double-blinded randomized controlled trial. J Clin Hypertens. 2019;21:1002–8. https://​doi.​org/​10.​1111/​jch.​13557.CrossRef
34.
Redon J, Pichler G. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J Hypertens. 2016;34:359–67.CrossRefPubMed
35.
Ramirez AJ, Sanchez MJ, Sanchez RA. Diabetic patients with essential hypertension treated with amlodipine. J Hypertens. 2019;37:636–42.CrossRefPubMed
36.
37.
Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17:495–501.CrossRefPubMed
38.
Philipp T, Glazer RD, Wernsing M, Yen J. Initial combination therapy with amlodipine/valsartan compared with monotherapy in the treatment of hypertension. J Am Soc Hypertens. 2011;5:417–24.CrossRefPubMed
39.
Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587–604.CrossRefPubMed
40.
Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens. 2009;11:207–13.CrossRef
41.
Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011;377:312–20.CrossRefPubMed
42.
Packard KA, Wurdeman RL, Arouni AJ. ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction. Ann Pharmacother. 2002;36:1058–67.CrossRefPubMed
43.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.CrossRefPubMed
44.
Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NRC, et al. The 2010 Canadian hypertension education program recommendations for the management of hypertension: part 2—therapy. Can J Cardiol. 2010;26:249–58.CrossRefPubMedPubMedCentral
45.
46.
47.
48.
Mourad J-J, Waeber B, Zannad F, Laville M, Duru G, Andrjak M. Comparison of different therapeutic strategies in hypertension. J Hypertens. 2004;22:2379–86.CrossRefPubMed
49.
50.
51.
Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, et al., editors. Cochrane Handb. Syst. Rev. Interv. Boca Raton: Wiley; 2019. p. 375–402.CrossRef
Metadaten
Titel
Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis
verfasst von
Sadek Mostafa
Hosam Shabana
Farag Khalil
Ismail Mohamed El Mancy
Hendawy Abdel-Moety Zedan
Ahmed Elmoursi
Ibrahim Ghounim Ramadan
Saad El Deen Mohamed
Arafat Kassem
Islam Shawky Kamel
Publikationsdatum
01.11.2022
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 6/2022
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-022-00544-3

Weitere Artikel der Ausgabe 6/2022

High Blood Pressure & Cardiovascular Prevention 6/2022 Zur Ausgabe

Letter to the Editor

Cardiovascular Risk in Patients with Chronic Kidney Disease with Special Reference to Statin Therapy

Original article

Evaluating Adherence to Concomitant Diabetes, Hypertension, and Hyperlipidemia Treatments and Cardiovascular Outcomes Among Elderly Patients Using Marginal Structural Modeling

Review article

Subclinical HMOD in Hypertension: Left Ventricular Diastolic Dysfunction

Original Article

Air Pollution and Home Blood Pressure: The 2021 Athens Wildfires

Original article

The Association Between Dietary Inflammatory Index (DII) and Risk of Hypertension: A Case–Control Study

Review article

Device-Based Therapy for Resistant Hypertension: An Up‐to‐Date Review

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise